Abstract |
Although numerous second-generation isoprenylation inhibitors are proposed or under investigation for the treatment and/or prevention of cancer (eg, R115777, SCH 66336, L-778,123, BMS-214662), the chemotherapeutic and chemopreventive potential of commonly prescribed first-generation isoprenylation inhibitors, the statins, and other classes of lipid-lowering medications, the fibrates, has yet to be seriously explored. Two lipid-lowering medications, lovastatin and gemfibrozil, have been associated with a decreased incidence of melanoma in large, prospective, randomized, double-blind, placebo-controlled clinical cardiology trials. This article reviews melanoma biology and the clinical evidence for the use of lipid-lowering medications for melanoma chemoprevention and/or adjuvant chemotherapy.
|
Authors | Robert P Dellavalle, M Kelly Nicholas, Lisa M Schilling |
Journal | American journal of therapeutics
(Am J Ther)
2003 May-Jun
Vol. 10
Issue 3
Pg. 203-10
ISSN: 1075-2765 [Print] United States |
PMID | 12756427
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)
|
Chemical References |
- Anticarcinogenic Agents
- Anticholesteremic Agents
- Antineoplastic Agents
- Lovastatin
- Gemfibrozil
|
Topics |
- Anticarcinogenic Agents
(therapeutic use)
- Anticholesteremic Agents
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Chemoprevention
(methods)
- Gemfibrozil
(therapeutic use)
- Humans
- Lovastatin
(therapeutic use)
- Melanoma
(drug therapy, prevention & control)
- Meta-Analysis as Topic
- Prospective Studies
- Randomized Controlled Trials as Topic
|